Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation

NCT00563108 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

Graft vs Host Disease
Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Basiliximab
DRUG: Placebo

Sponsor

Hospital Authority, Hong Kong

Collaborators

[object Object]
[object Object]